Filing Flows › Capricor Therapeutics (CAPR) › Q4 2024 › vs Q4 2023
Capricor Therapeutics (CAPR) Q4 2024 vs Q4 2023 (year over year)
Capricor Therapeutics's revenue fell $958K (-8%) from $12.1M in Q4 2023 to $11.1M in Q4 2024.
Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%, net loss $7.1M, operating cash flow −$14.8M. The chart draws each line against Q4 2023, the increases inside each band.
Every line
| Line | Q4 2024 | Q4 2023 | Change | % |
|---|---|---|---|---|
| Revenue | $11.1M | $12.1M | −$958K | -8% |
| Other income, net | $580K | $519K | $60K | +12% |
| Net loss | $7.1M | $762K | $6.4M | +834% |
| Costs & expenses | $18.8M | $13.4M | $5.5M | +41% |
| Operating costs | $18.8M | $13.4M | $5.5M | +41% |
| Research & development | $14.6M | $9.9M | $4.6M | +46% |
| General & admin | $4.3M | $3.4M | $843K | +25% |
| Operating cash sources | $17.5M | $13.8M | $3.7M | +27% |
| Depreciation | $376K | $308K | $68K | +22% |
| Share-based compensation | $2.3M | $1.9M | $434K | +23% |
| Cash used in operations | $14.8M | $11.6M | $3.2M | +28% |
| Net loss absorbed | $7.1M | $762K | $6.4M | +834% |
| Working capital & other | $10.4M | $13.0M | −$2.7M | -20% |
Questions
How much did Capricor Therapeutics's revenue grow year over year in Q4 2024?
Capricor Therapeutics's revenue fell $958K (-8%) from $12.1M in Q4 2023 to $11.1M in Q4 2024.